VKTX vs the Top Picks average
| Pillar | VKTX | Book avg | Diff |
|---|---|---|---|
| Quality | 0.23 | 0.83 | -0.59 |
| Growth | 0.10 | 0.91 | -0.81 |
| Value | 0.04 | 0.75 | -0.71 |
Averaged across the 30 names in today's Top Picks (mean score 81.8). A name can beat these averages and still be absent from the book — it also applies concentration limits.
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Viking Therapeutics, Inc. (VKTX): score, valuation & FAQ
Viking Therapeutics, Inc. (VKTX) is a Biotechnology company that scores 10.5 out of 100 on the Bull Rankings quality-growth model — a weak reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (A), while FCF (F) rate weaker.
Is VKTX a good stock to buy?
Bull Rankings scores VKTX 10.5 out of 100 on its quality-growth model, which is a weak reading. That is driven by D/E (A). A score is a quantitative screen of Viking Therapeutics, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does VKTX score 10.5 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). VKTX earns its highest marks on D/E (A), and is held back by FCF (F). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is VKTX overvalued or undervalued?
We don't compute a reliable discounted-cash-flow value for VKTX — typically because it is not yet consistently profitable or free-cash-flow positive — so its valuation rests on growth and price-to-sales rather than on earnings-based intrinsic value. Judge it on the trajectory of the business, not a single multiple.
What are the main risks of investing in VKTX?
Free cash flow is negative (-$418m) — capital raises or debt issuance likely required; dilution / leverage risk. ROE -131% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.